bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1

Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2

2

isolates from Pennsylvania

3
4

Ahmed M. Moustafa1,2, Colleen Bianco1, Lidiya Denu1, Azad Ahmed3, Brandy Neide1,

5

John Everett4, Shantan Reddy4, Emilie Rabut5, Jasmine Deseignora5, Michael D.

6

Feldman6, Kyle G. Rodino6, Frederic Bushman4, Rebecca M. Harris6,7, Josh Chang

7

Mell3, Paul J. Planet1,7,8*

8
9
10

1. Division of Pediatric Infectious Diseases, Children’s Hospital of Philadelphia,
Philadelphia, PA 19104, USA.

11
12

2. Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of

13

Philadelphia, Philadelphia, PA 19104, USA.

14
15

3. Department of Microbiology and Immunology, Center for Genomic Sciences,

16

Drexel University College of Medicine, Philadelphia, PA 19129, USA.

17
18

4. Department of Microbiology, Perelman School of Medicine, University of

19

Pennsylvania, Philadelphia, PA 19104, USA.

20
21

5. Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

22

1

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

23

6. Department of Pathology and Laboratory Medicine, Perelman School of

24

Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

25
26

7. Department of Pediatrics, Perelman College of Medicine, University of

27

Pennsylvania, Philadelphia, PA 19104, USA.

28
29

8. Sackler Institute for Comparative Genomics, American Museum of Natural

30

History, New York, NY 10024, USA.

31
32

Phone

33

PJP: +1 215-590-1169

34

*Corresponding Author

35

Emails

36

AMM: moustafaam@chop.edu

37

PJP: planetp@chop.edu

2

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

38

Abstract

39

Rapid whole genome sequencing of SARS-CoV-2 has presented the ability to detect

40

new emerging variants of concern in near real time. Here we report the genome of a

41

virus isolated in Pennsylvania in March 2021 that was identified as lineage B.1.1.7

42

(VOC-202012/01) that also harbors the E484K spike mutation, which has been shown

43

to promote “escape” from neutralizing antibodies in vitro. We compare this sequence to

44

the only 5 other B.1.1.7+E484K genomes from Pennsylvania, all of which were isolated

45

in mid March. Beginning in February 2021, only a small number (n=60) of isolates with

46

this profile have been detected in the US, and only a total of 253 have been reported

47

globally (first in the UK in December 2020). Comparative genomics of all currently

48

available high coverage B.1.1.7+E484K genomes (n=235) available on GISAID

49

suggested the existence of 7 distinct groups or clonal complexes (CC; as defined by

50

GNUVID) bearing the E484K mutation raising the possibility of 7 independent

51

acquisitions of the E484K spike mutation in each background. Phylogenetic analysis

52

suggested the presence of at least 3 distinct clades of B.1.1.7+E484K circulating in the

53

US, with the Pennsylvanian isolates belonging to two distinct clades. Increased genomic

54

surveillance will be crucial for detection of emerging variants of concern that can escape

55

natural and vaccine induced immunity.

56

3

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

57

During the past six months of the pandemic several variants of concern (VOC), each

58

represented by a constellation of specific mutations thought to enhance viral fitness,

59

have emerged in viral lineages from the UK (20I/501Y.V1; B.1.1.7), South Africa

60

(20H/501Y.V2; B.1.351), and Brazil (20J/501Y.V3; P.1). These lineages were

61

concerning due to likely increased transmission rates1-6. Two of these lineages, B.1.351

62

and P.1 were of specific concern because they harbor the mutation E484K, which has

63

been shown to enhance escape from neutralizing antibody inhibition in vitro7, and may

64

be associated with reduced efficacy of the vaccine8-11. In general, viruses from the

65

B.1.1.7 lineage do not harbor this mutation. However, in February 2021 Public Health

66

England (PHE) published a concerning report of eleven B.1.1.7 genomes that had

67

acquired the E484K spike mutation12.

68

Here we report a B.1.1.7 isolate with the E484K spike mutation isolated in

69

southeastern Pennsylvania (PA). Our laboratory at the Children’s hospital of

70

Philadelphia performed sequencing on randomly selected isolates collected since

71

January 2021. Figure 1A shows the diversity of 114 randomly sequenced genomes.

72

Lineages B.1.1.7, B.1.429 (California), B.1.526 (New York) and R.1 (International

73

lineage with the E484K mutation) accounted for 69% of the sequenced genomes in

74

March. There was a massive increase in lineage B.1.1.7 from 2% (1/47) in February to

75

42% in March (15/36). Interestingly, one B.1.1.7 isolate carried the E484K spike

76

mutation that is present in the South African and Brazilian lineages.

77

To better understand the relationship between this isolate and publicly available

78

SARS-CoV-2 genomes, we compared it to all available B.1.1.7+E484K high coverage

79

genomes available on GISAID13 (n=235). Since the first report by PHE in February, a

4

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

80

total of 253 B.1.1.7+E484K genomes have been uploaded to GISAID from England and

81

14 other countries (Germany, France, Italy, Poland, Sweden, Ireland, Netherlands,

82

Portugal, Wales, Turkey, Slovakia, Austria, Czech Republic and USA)13 (as of

83

04/17/2021).

84

A temporal plot of the number of B.1.1.7+E484K isolates collected between

85

December 2020 to March 2021 (2-week window) is shown in Figure 1B. The first

86

isolate of the 60 US isolates available on GISAID was collected on 02/06/2021 from

87

Oregon (OR). Isolates were also reported from 15 other states (New York, North

88

Carolina, Connecticut, Georgia, New Jersey, Maryland, Florida, West Virginia,

89

California, Pennsylvania, Michigan, Texas, Massachusetts, Washington, and Colorado).

90

Of these isolates 48% were from Florida (n=17) and New York (n=12) and 28% were

91

from New Jersey (n=7), California (n=4) and Pennsylvania (n=6). Two isolates were

92

from Oregon (OR), Connecticut (CT), Maryland (MD), and single isolates are recorded

93

from Georgia (GA), Texas (TX), Massachusetts (MA), Washington (WA), Colorado

94

(CO), West Virginia (WV), Michigan (MI), and North Carolina (NC). The number of US

95

isolates in March (n=47 including the PA isolates) was nearly 6 times the number of the

96

isolates reported in February. This increase raises the concern that more

97

B.1.1.7+E484K sequences may be emerging even as herd immunity increases by

98

natural immunity and vaccines.

99

Although all 236 genomes were typed as B.1.1.7 using Pangolin14, a more granular

100

view using our typing tool “GNUVID”15 shows that they belong to 7 different clonal

101

complexes (CCs 45062, 46649, 49676, 57630, 58534, 62415 and 67441) (Figure 1C

102

and Supplementary Table 1). In the GNUVID typing system, these correspond to 7 of

5

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

103

10 CCs in the B.1.1.7 lineage. For each of these CCs, representative sequences

104

without the E484K mutation have been circulating since at least November 2020,

105

predating the first E484K in each CC. This raises the possibility that the E484K mutation

106

was acquired independently in each of these CCs in independent events.

107

Phylogenetic analysis of the 235 B.1.1.7+E484K GISAID isolates showed that

108

US isolates are found in at least 3 different clades. The genome presented here falls in

109

a well-supported clade of 28 isolates, 6 of which were from the US (CT, FL, OR, PA and

110

NY), 18 from Sweden, 2 from Poland and 1 from Germany (Figure 2A). The only other

111

4 isolates reported from PA, were in a large clade containing the majority of US

112

genomes, and were located in a well-supported subclade with genomes from the nearby

113

state of West Virginia.

114

Analysis of SNPs in the 236 isolates compared to the reference MN908947.316

115

(Figure 2B and Supplementary Figure 1) showed that the isolate presented here had

116

12/17 of the B.1.1.7 defining SNPs (Supplementary Table 2), while the other

117

Pennsylvanian isolate in the same clade had 17/17 of the SNPs. It also shared with 9

118

other US isolates a stop mutation (A28095T) in ORF8 (Figure 2B).

119

Here we present a comparative analysis of the first SARS-CoV-2 B.1.1.7 isolates

120

detected in PA that harbor the E484K spike mutation, a mutation that could be

121

associated with reduced efficacy of both vaccine-induced and natural immunity. Our

122

analysis suggests that multiple lineages of B.1.1.7+E484K are circulating in the US, and

123

that these lineages may have acquired E484K independently.

124
125

Methods

6

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

126

A nasopharyngeal swab sample that had residual volume after initial laboratory

127

processing, positive PCR testing for SARS-CoV-2, was obtained for this study. RNA

128

was extracted from nasopharyngeal swab samples using QIAamp Viral RNA Mini

129

(Qiagen). Whole genome sequencing was done by The Genomics Core Facility at

130

Drexel University. Briefly, WGS of extracted viral RNA was performed as previously

131

described using Paragon Genomics CleanPlex SARS-CoV-2 Research and

132

Surveillance NGS Panel17,18. Libraries were quantified using the Qubit dsDNA HS (High

133

Sensitivity) Assay Kit (Invitrogen) with the Qubit Fluorometer (Invitrogen). Library quality

134

was assessed using Agilent High Sensitivity DNA Kit and the 2100 Bioanalyzer

135

instrument (Agilent). Libraries were then normalized to 5nM and pooled in equimolar

136

concentrations. The resulting pool was quantified again using the Qubit dsDNA HS

137

(High Sensitivity) Assay Kit (Invitrogen) and diluted to a final concentration of 4nM;

138

libraries were denatured and diluted according to Illumina protocols and loaded on the

139

MiSeq at 10pM. Paired-end and dual-indexed 2x150bp sequencing was done using

140

MiSeq Reagent Kits v3 (300 cycles). Sequences were demultiplexed and basecalls

141

were converted to FASTQ using bcl2fastq2 v2.20. The FASTQ reads were then

142

processed to consensus sequence and variants were identified using the ncov2019-

143

artic-nf pipeline (https://github.com/connor-lab/ncov2019-artic-nf). Briefly, the pipeline

144

uses iVar19 for primer trimming and consensus sequence making (options: --

145

ivarFreqThreshold 0.75). A bed file for the Paragon kit primers was used in the pipeline.

146

All 253 SARS-CoV-2 genomes that were assigned to Pango lineage14 B.1.1.7

147

and possessing the E484K spike mutation (including the study isolate CHOP_204) were

148

downloaded from GISAID13 on 04/17/2021. An acknowledgement table of the submitting

7

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

149

laboratories providing the SARS-CoV-2 genomes used in this study is in Supplemental

150

Table 3. Seventeen sequences were excluded for lower coverage (> 5% Ns) (n=14)

151

and missing collection date (n=3). All the high coverage SARS-CoV-2 genomes (n=236)

152

were assigned a clonal complex using the GNUVID v2.2 database (version January 6th

153

2021)15. Temporal plots were plotted in GraphPad Prism v7.0a.

154

To show the relationship amongst the genomes of the 236 isolates, a maximum

155

likelihood tree was constructed. Briefly, consensus SARS-CoV-2 sequences for the 236

156

isolates were aligned to MN908947.316 using MAFFT’s FFT-NS-2 algorithm 20 (options:

157

--add --keeplength)). The 5’ and 3’ untranslated regions were masked in the alignment

158

file using a custom script. A maximum likelihood tree using IQ-TREE 221 was then

159

estimated using the GTR+F+I model of nucleotide substitution22, default heuristic search

160

options, and ultrafast bootstrapping with 1000 replicates23. The tree was rooted to

161

MN908947.3. The snipit tool was then used to summarize the SNPs in the 236 isolates

162

relative to MN908947.3 (https://github.com/aineniamh/snipit).

163

The sample was obtained by as part of routine clinical care, solely for non-

164

research purposes, carrying minimal risk, and were therefore granted a waiver of

165

informed consent as reviewed under protocol number under IRB 21-018478.

166
167

Availability of data and material

168

The sequence has been uploaded to GISAID with accession number

169

EPI_ISL_1629709.

170
171

Conflict of interest

8

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

172

The authors declare that they have no competing interests.

173
174

Acknowledgements

175

We would like to thank the Global Initiative on Sharing All Influenza Data (GISAID) and

176

thousands of contributing laboratories for making the genomes publicly available. A full

177

acknowledgements table is available in Supplementary Table 3. We would like to

178

acknowledge the staff members of the Drexel Genomics Core Facility at the Drexel

179

University College of Medicine for processing and sequencing the isolates. P.J.P and

180

A.M.M are supported by 1R01AI137526-01 and 1R21AI144561-01A1 (A.M.M. and

181

P.J.P.), and R01NR015639 (P.J.P.).

182
183

9

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

184

Figure Legends

185

Figure 1. Diversity of SARS-CoV-2 in Philadelphia and global diversity of

186

sequenced B.1.1.7+E484K genomes. A. Stacked bar plot showing the diversity of

187

random genomes sequenced by our laboratory at Children’s Hospital of Philadelphia

188

during January, February and March 2021. Ten lineages that were represented by only

189

one genome (B.1.1, B.1.1.106, B.1.1.129, B.1.1.197, B.1.1.281, B.1.1.296, B.1.119,

190

B.1.234, B.1.350, B.1.409) were excluded from the plot. One isolate that is B.1.526.1

191

was counted with the parent B.1.526 for easier visualization. B. Bar plot showing

192

number of GISAID genomes (n=250) that are 20I/501Y.V1 and have the E484K spike

193

mutation over time in the US and globally. C. Diversity of 236 isolates according to

194

GNUVID. Bar plot showing relative abundance of circulating clonal complexes (CC) for

195

the 236 B.1.1.7+E484K isolates (typed by GNUVID). The bar plot shows that the

196

isolates belong to 7 different CCs. Isolate EPI_ISL_1385215 was not assigned to any of

197

the 7 CCs (CC255). Fourteen isolates were excluded from the plot as they had > 5%

198

nucleotides designated “N” in the sequence.

199

Figure 2. SNP-based Phylogeny and variations of the B.1.1.7+E484K isolates. A.

200

Maximum likelihood tree of the B.1.1.7+E484K isolates. US isolates are in red. For the

201

CHOP_204 isolate the alternative allele was called as consensus if its frequency was at

202

least 0.75. The tree was rooted with MN908947.3. Bootstrap values are shown on the

203

branches. B. SNP patterns in the 53 US isolates compared to MN908947.3. SNP

204

variations in the 236 isolates are shown in Supplementary Figure 1. Mutations identified

205

in CHOP_204 are available in Supplementary Table 2. Seven US isolates were

206

excluded from the plot as they had > 5% nucleotides designated “N” in the sequence.

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

207

An acknowledgement table of the submitting laboratories providing the SARS-CoV-2

208

genomes used in this study is in Supplemental Table 3.

209

11

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

210

Figure 1

A50
50

B.1.1.7

B.1.1.7
R.1
R.1
B.1.526B.1.526

40
40

B.1.429B.1.429
B.1.243B.1.243
Genomes
Genomes

30
30

B.1.2

B.1.2

B.1

B.1

20

20

B.1.369
B.1.369
B.1.311
B.1.311
B.1.196
B.1.196
B.1.1.304

10

B.1.361

B.1.1.304

B.1.1.29B.1.361

10

B.1.1.29
B.1.1.222
0

B

0

B.1.1.222
January

January

February

February

March

March
Other Countries
USA

Number of Sequenced Genomes

100

80

60

40

20

0

End_Dec Mid_Jan End_Jan Mid_Feb End_Feb Mid_Mar End_Mar Mid_Apr

C
Number of Sequenced Genomes

100

CC58534
CC57630

80

CC49676
CC46649

60

CC45062
CC67441

40

CC62415

20
0

End_Dec Mid_Jan End_Jan Mid_Feb End_Feb Mid_Mar End_Mar Mid_Apr

211

12

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

212

Figure 2

A

hCoV-19/England/ALDP-1306B12/2021|EPI_ISL_1100560|2021-02-20
8hCoV-19/England/QEUH-1309881/2021|EPI_ISL_1333236|2021-02-21
6hCoV-19/England/ALDP-136DB0A/2021|EPI_ISL_1205721|2021-03-01

hCoV-19/England/LIVE-DFB593/2021|EPI_ISL_1104425|2021-02-09

11
4hCoV-19/England/ALDP-128E982/2021|EPI_ISL_1045160|2021-02-11
6
9
326hCoV-19/England/CAMC-132372A/2021|EPI_ISL_1333966|2021-02-23

hCoV-19/England/ALDP-136DBBF/2021|EPI_ISL_1205714|2021-03-01
hCoV-19/England/ALDP-12C5266/2021|EPI_ISL_1176993|2021-02-15
hCoV-19/England/QEUH-13098AF/2021|EPI_ISL_1333216|2021-02-21
4hCoV-19/England/ALDP-EE4936/2021|EPI_ISL_835036|2021-01-04
5
6hCoV-19/Wales/ALDP-101BF7B/2021|EPI_ISL_879765|2021-01-13
4
1
9hCoV-19/England/ALDP-1090178/2021|EPI_ISL_885376|2021-01-15
9
hCoV-19/England/ALDP-EE4A24/2021|EPI_ISL_835003|2021-01-04
1
hCoV-19/England/ALDP-10E21B3/2021|EPI_ISL_908474|2021-01-17
8hCoV-19/England/QEUH-11CA824/2021|EPI_ISL_957114|2021-01-31
1hCoV-19/England/QEUH-F89914/2021|EPI_ISL_851504|2021-01-08
00
hCoV-19/England/QEUH-F8999C/2021|EPI_ISL_851507|2021-01-08
10
hCoV-19/England/ALDP-100441C/2021|EPI_ISL_864004|2021-01-11
hCoV-19/Netherlands/UT-RIVM-12844/2021|EPI_ISL_1020302|2021-02-03
8hCoV-19/Netherlands/NH-RIVM-16007/2021|EPI_ISL_1232682|2021-02-21
1
hCoV-19/Netherlands/UT-RIVM-13864/2021|EPI_ISL_1089490|2021-02-04
100
hCoV-19/Netherlands/UT-RIVM-16606/2021|EPI_ISL_1289022|2021-03-02
9hCoV-19/Netherlands/UT-RIVM-20214/2021|EPI_ISL_1455912|2021-03-08
9
18
hCoV-19/Netherlands/UT-RIVM-16662/2021|EPI_ISL_1289029|2021-03-02
8
hCoV-19/England/ALDP-1279207/2021|EPI_ISL_1018343|2021-02-09
hCoV-19/England/BRIS-263E78/2021|EPI_ISL_1545801|2021-02-25
hCoV-19/England/ALDP-CB4500/2020|EPI_ISL_761305|2020-12-18
hCoV-19/England/ALDP-121F76E/2021|EPI_ISL_987108|2021-02-02
hCoV-19/England/ALDP-1016BE5/2021|EPI_ISL_880971|2021-01-13
hCoV-19/England/ALDP-10E2010/2021|EPI_ISL_908354|2021-01-19
hCoV-19/England/ALDP-10E2001/2021|EPI_ISL_908386|2021-01-19
hCoV-19/England/ALDP-10149DE/2021|EPI_ISL_881370|2021-01-13
hCoV-19/England/ALDP-13630D8/2021|EPI_ISL_1207256|2021-02-26
20
hCoV-19/England/ALDP-12032D5/2021|EPI_ISL_988812|2021-02-02
22
hCoV-19/England/ALDP-F82131/2021|EPI_ISL_846335|2021-01-08
25
hCoV-19/England/ALDP-119CC4D/2021|EPI_ISL_945381|2021-01-27
hCoV-19/England/MILK-128157C/2021|EPI_ISL_1045593|2021-02-06
17
5hCoV-19/England/ALDP-115B6B5/2021|EPI_ISL_991635|2021-01-24
hCoV-19/England/ALDP-EE1F73/2021|EPI_ISL_835007|2021-01-03
7
9hCoV-19/England/ALDP-1016C3D/2021|EPI_ISL_881226|2021-01-13
9
hCoV-19/England/MILK-118D966/2021|EPI_ISL_958243|2021-01-26
19
hCoV-19/England/MILK-12C6793/2021|EPI_ISL_1248566|2021-02-16
hCoV-19/England/ALDP-CEFD6E/2020|EPI_ISL_782148|2020-12-17
12
8hCoV-19/England/ALDP-1014A08/2021|EPI_ISL_881376|2021-01-13
hCoV-19/England/ALDP-11BE8D8/2021|EPI_ISL_969661|2021-01-29
hCoV-19/England/BRIS-262565/2021|EPI_ISL_1247469|2021-02-17
10
0
hCoV-19/England/CAMC-13402F9/2021|EPI_ISL_1206501|2021-02-17
15
hCoV-19/England/CAMC-135A98E/2021|EPI_ISL_1333819|2021-02-09
27
hCoV-19/England/BRIS-262626/2021|EPI_ISL_1247474|2021-02-17
29
hCoV-19/England/ALDP-143F317/2021|EPI_ISL_1410622|2021-03-21
hCoV-19/Portugal/PT3566/2021|EPI_ISL_1116781|2021-02-07
6310
hCoV-19/England/MILK-13E335F/2021|EPI_ISL_1325124|2021-03-13
62
hCoV-19/England/PHWC-4CAF4D/2021|EPI_ISL_1105933|2021-02-10
hCoV-19/Poland/NIPH-NIH_ECDC-2787/2021|EPI_ISL_1627710|2021-03-23
hCoV-19/England/MILK-14726B5/2021|EPI_ISL_1468017|2021-03-23
38
22
hCoV-19/England/ALDP-1478312/2021|EPI_ISL_1488119|2021-03-25
32
3hCoV-19/England/MILK-1440AA5/2021|EPI_ISL_1411771|2021-03-21
9
hCoV-19/England/MILK-1440692/2021|EPI_ISL_1411717|2021-03-21
100
hCoV-19/England/MILK-148A32C/2021|EPI_ISL_1487655|2021-03-26
hCoV-19/England/QEUH-1499506/2021|EPI_ISL_1486118|2021-03-28
4hCoV-19/USA/CA-CDC-STM-000040794/2021|EPI_ISL_1554495|2021-03-17
8
5hCoV-19/USA/FL-CDC-STM-000044978/2021|EPI_ISL_1592565|2021-03-26
1
8hCoV-19/USA/CA-CDC-QDX23356637/2021|EPI_ISL_1582032|2021-03-26
5
1hCoV-19/USA/CA-CDC-FG-019366/2021|EPI_ISL_1614046|2021-04-02
00
91
hCoV-19/USA/CA-CDC-FG-018313/2021|EPI_ISL_1614834|2021-04-06
46
hCoV-19/USA/OR-MAP000321/2021|EPI_ISL_1531761|2021-03-29
hCoV-19/USA/NY-Wadsworth-21028862-01/2021|EPI_ISL_1397673|2021-03-01
19
hCoV-19/USA/NY-PRL-2021_03_15_01A02/2021|EPI_ISL_1306750|2021-03-13
88
hCoV-19/USA/NJ-CDC-LC0023856/2021|EPI_ISL_1422066|2021-02-24
80
hCoV-19/USA/NC-UNC-0380/2021|EPI_ISL_1240901|2021-02-25
6
hCoV-19/USA/NJ-CDC-ASC210011116/2021|EPI_ISL_1563386|2021-03-18
99
hCoV-19/USA/NJ-CDC-LC0036656/2021|EPI_ISL_1609898|2021-03-23
98
hCoV-19/USA/NJ-CDC-LC0028237/2021|EPI_ISL_1548232|2021-03-12
15
9hCoV-19/USA/NY-PRL-2021_03_01_00E03/2021|EPI_ISL_1172424|2021-02-26
8
10
hCoV-19/USA/NY-PRL-03_10_00K08/2021|EPI_ISL_1258584|2021-03-08
2hCoV-19/USA/FL-CDC-FG-009909/2021|EPI_ISL_1555203|2021-03-12
4
2hCoV-19/USA/FL-CDC-FG-011916/2021|EPI_ISL_1555559|2021-03-08
hCoV-19/USA/NJ-CDC-QDX23396252/2021|EPI_ISL_1582107|2021-03-28
118
8hCoV-19/USA/FL-CDC-STM-000040476/2021|EPI_ISL_1554345|2021-03-18
hCoV-19/USA/FL-CDC-FG-011797/2021|EPI_ISL_1555522|2021-03-08
hCoV-19/USA/MA-CDC-LC0037228/2021|EPI_ISL_1610474|2021-03-29
9hCoV-19/Germany/BB-RKI-I-038813/2021|EPI_ISL_1285174|2021-03-08
9
81
hCoV-19/Germany/BB-RKI-I-038814/2021|EPI_ISL_1285175|2021-03-07
22
hCoV-19/Ireland/CW-NVRL-t21IRL41854/2021|EPI_ISL_1323808|2021-02-23
99
83
hCoV-19/USA/NY-PRL-2021_0405_02D15/2021|EPI_ISL_1542234|2021-04-02
hCoV-19/USA/FL-CDC-STM-000040889/2021|EPI_ISL_1554512|2021-03-21
hCoV-19/Wales/PHWC-4AF5F1/2020|EPI_ISL_822694|2020-12-29
8hCoV-19/USA/FL-CDC-ASC210019190/2021|EPI_ISL_1561041|2021-03-24
7
9hCoV-19/USA/FL-CDC-ASC210009424/2021|EPI_ISL_1562092|2021-03-17
9
hCoV-19/USA/FL-CDC-FG-013327/2021|EPI_ISL_1556270|2021-03-18
58
hCoV-19/USA/TX-CDC-STM-000044844/2021|EPI_ISL_1592444|2021-03-27
100
hCoV-19/USA/CO-CDPHE-2100719051/2021|EPI_ISL_1617248|2021-03-29
100
66
hCoV-19/USA/WA-UW-2021040104871/2021|EPI_ISL_1616622|2021-04-01
100
32
hCoV-19/USA/FL-CDC-STM-000030816/2021|EPI_ISL_1480225|2021-03-06
hCoV-19/USA/FL-CDC-LC0029834/2021|EPI_ISL_1548676|2021-03-18
61
8hCoV-19/USA/FL-CDC-STM-000034618/2021|EPI_ISL_1554137|2021-03-12
5
hCoV-19/USA/FL-CDC-FG-014160/2021|EPI_ISL_1556044|2021-03-17
93
hCoV-19/USA/FL-CDC-STM-000035440/2021|EPI_ISL_1553367|2021-03-13
9793
hCoV-19/USA/NY-Wadsworth-21028859-01/2021|EPI_ISL_1397670|2021-03-01
97
hCoV-19/USA/MD-IGS-012107506566A/2021|EPI_ISL_1608677|2021-03-16
hCoV-19/USA/MI-UM-S768053/2021|EPI_ISL_1585913|2021-03-27
17
1hCoV-19/USA/PA-CDC-STM-000042815/2021|EPI_ISL_1575645|2021-03-23
00
99
hCoV-19/USA/PA-CDC-STM-000044748/2021|EPI_ISL_1581406|2021-03-27
91
1 0 0 hCoV-19/USA/PA-CDC-STM-000041992/2021|EPI_ISL_1575849|2021-03-23
100
hCoV-19/USA/PA-CDC-STM-000042282/2021|EPI_ISL_1576144|2021-03-22
89
hCoV-19/USA/WV-CDC-LC0034449/2021|EPI_ISL_1549960|2021-03-18
84
hCoV-19/England/CAMC-11D4256/2021|EPI_ISL_1047721|2021-01-30
98
1hCoV-19/England/CAMC-106F1BE/2021|EPI_ISL_908202|2021-01-16
00
hCoV-19/England/CAMC-106F28E/2021|EPI_ISL_908209|2021-01-16
hCoV-19/England/ALDP-134D58A/2021|EPI_ISL_1189089|2021-02-23
3
44
hCoV-19/England/MILK-11539A5/2021|EPI_ISL_939292|2021-01-22
hCoV-19/England/CAMC-115EB77/2021|EPI_ISL_938238|2021-01-24
2hCoV-19/England/LOND-13266A2/2021|EPI_ISL_920689|2021-01-06
5
hCoV-19/England/LOND-13266B1/2021|EPI_ISL_920690|2021-01-21
hCoV-19/England/QEUH-12B7689/2021|EPI_ISL_1069921|2021-02-16
hCoV-19/England/QEUH-13BFDC7/2021|EPI_ISL_1275545|2021-03-09
hCoV-19/England/QEUH-13BFBBE/2021|EPI_ISL_1275490|2021-03-09
8hCoV-19/England/ALDP-12F8798/2021|EPI_ISL_1114929|2021-02-18
2
9hCoV-19/England/ALDP-12EA984/2021|EPI_ISL_1101487|2021-02-18
9
1 0 0 hCoV-19/England/ALDP-1315C59/2021|EPI_ISL_1308159|2021-02-21
hCoV-19/England/ALDP-1315DCF/2021|EPI_ISL_1308177|2021-02-21
5hCoV-19/England/QEUH-12FCEAE/2021|EPI_ISL_1175868|2021-02-21
0
6
hCoV-19/England/QEUH-1353BBC/2021|EPI_ISL_1334058|2021-02-26
hCoV-19/England/QEUH-1374FE6/2021|EPI_ISL_1245353|2021-03-03
hCoV-19/England/QEUH-1353E95/2021|EPI_ISL_1334074|2021-02-26
140
60
2hCoV-19/England/ALDP-1366BC5/2021|EPI_ISL_1186598|2021-02-26
3
hCoV-19/England/ALDP-1366D1A/2021|EPI_ISL_1186739|2021-02-26
23
hCoV-19/England/QEUH-13A868A/2021|EPI_ISL_1276592|2021-03-07
6hCoV-19/England/ALDP-1170104/2021|EPI_ISL_932020|2021-01-25
9
6hCoV-19/England/ALDP-1182D0B/2021|EPI_ISL_991123|2021-01-25
6
99
hCoV-19/England/ALDP-13FF824/2021|EPI_ISL_1342703|2021-03-15
hCoV-19/England/ALDP-1182345/2021|EPI_ISL_932032|2021-01-25
hCoV-19/England/MILK-1419207/2021|EPI_ISL_1415939|2021-03-18
hCoV-19/England/MILK-14C796D/2021|EPI_ISL_1536669|2021-04-03
hCoV-19/England/ALDP-14C6272/2021|EPI_ISL_1536532|2021-04-03
hCoV-19/England/MILK-14CCEF0/2021|EPI_ISL_1535394|2021-04-02
hCoV-19/England/ALDP-14C36E2/2021|EPI_ISL_1535771|2021-04-01
1
hCoV-19/England/ALDP-14AFB74/2021|EPI_ISL_1504295|2021-03-31
hCoV-19/England/ALDP-14C91DC/2021|EPI_ISL_1536850|2021-04-04
hCoV-19/England/ALDP-14C398F/2021|EPI_ISL_1535641|2021-04-02
hCoV-19/England/ALDP-14C6579/2021|EPI_ISL_1536308|2021-04-03
12
26
1hCoV-19/England/ALDP-14C8FA6/2021|EPI_ISL_1537040|2021-04-04
00
hCoV-19/England/ALDP-14D5823/2021|EPI_ISL_1564551|2021-04-06
26
211hCoV-19/England/ALDP-14D57BD/2021|EPI_ISL_1564656|2021-04-06
4
hCoV-19/England/MILK-14CB90F/2021|EPI_ISL_1535235|2021-04-03
28
hCoV-19/England/ALDP-14B0071/2021|EPI_ISL_1504129|2021-03-31
100
hCoV-19/England/MILK-14194E3/2021|EPI_ISL_1415951|2021-03-18
21
hCoV-19/England/MILK-14CD40C/2021|EPI_ISL_1535527|2021-04-04
hCoV-19/Switzerland/TI-ETHZ-550311/2020|EPI_ISL_1598498|2021-03-25
hCoV-19/Sweden/75682552R9/2021|EPI_ISL_1417738|2021-02-22
73
hCoV-19/Poland/PL-P946/2021|EPI_ISL_1497724|2021-03-22
99
1hCoV-19/England/CAMC-11AAA8E/2021|EPI_ISL_996993|2021-01-25
00
7
hCoV-19/England/CAMC-11AAAAC/2021|EPI_ISL_996995|2021-01-25
hCoV-19/England/QEUH-13293E4/2021|EPI_ISL_1174049|2021-02-24
19
hCoV-19/England/MILK-11EF953/2021|EPI_ISL_980572|2021-01-30
9hCoV-19/England/CAMC-13D42DC/2021|EPI_ISL_1327536|2021-03-18
9
hCoV-19/England/CAMC-141BE98/2021|EPI_ISL_1410170|2021-03-18
20
hCoV-19/England/CAMC-13231C2/2021|EPI_ISL_1246231|2021-02-20
hCoV-19/Poland/0146WSN2021_wsseol/2021|EPI_ISL_1300730|2021-03-11
96
hCoV-19/Italy/CAM-TIGEM-IZSM-COLLI-6659/2021|EPI_ISL_1447794|2021-03-17
7hCoV-19/Netherlands/NB-RIVM-23125/2021|EPI_ISL_1596007|2021-03-21
7
6hCoV-19/Netherlands/NB-RIVM-24036/2021|EPI_ISL_1596917|2021-03-30
6
1hCoV-19/Germany/NW-RKI-I-055597/2021|EPI_ISL_1439178|2021-03-20
00
28
hCoV-19/Netherlands/NB-RIVM-24001/2021|EPI_ISL_1596882|2021-03-30
hCoV-19/Austria/CeMM6574/2021|EPI_ISL_1583457|2021-03-09
5
9hCoV-19/Germany/BY-RKI-I-060970/2021|EPI_ISL_1566469|2021-03-27
8
hCoV-19/Germany/BY-RKI-I-060988/2021|EPI_ISL_1566487|2021-03-25
1173
hCoV-19/Germany/TH-RKI-I-028847/2021|EPI_ISL_1211960|2021-02-26
hCoV-19/Sweden/75682397R9/2021|EPI_ISL_1417975|2021-02-22
9251
hCoV-19/Czech
hCoV-19/Poland/NIPH-NIH_ECDC-3006/2021|EPI_ISL_1627967|2021-03-27
22
7hCoV-19/Sweden/4011198264/2021|EPI_ISL_1603909|2021-03-10
8
1hCoV-19/Sweden/4011443064/2021|EPI_ISL_1604246|2021-03-11
00
9hCoV-19/Sweden/75721528R9/2021|EPI_ISL_1605765|2021-03-19
8
hCoV-19/Sweden/75727902R9/2021|EPI_ISL_1606419|2021-03-24
8hCoV-19/Germany/BY-RKI-I-070292/2021|EPI_ISL_1574410|2021-04-01
2
15
11
1hCoV-19/France/PDL-IPP08546/2021|EPI_ISL_1594447|2021-03-30
00
25
hCoV-19/Germany/BY-RKI-I-070531/2021|EPI_ISL_1574635|2021-04-02
22
hCoV-19/France/IDF-IPP07562/2021|EPI_ISL_1517226|2021-03-22
hCoV-19/France/IDF-IPP07563/2021|EPI_ISL_1517227|2021-03-22
36
hCoV-19/France/IDF-IPP07340/2021|EPI_ISL_1517094|2021-03-23
11070
hCoV-19/France/HDF-IPP08695/2021|EPI_ISL_1621793|2021-03-25
hCoV-19/France/IDF-IPP08303/2021|EPI_ISL_1621700|2021-03-28
6hCoV-19/Germany/RP-RKI-I-067248/2021|EPI_ISL_1572035|2021-03-26
6
8
7hCoV-19/Germany/RP-RKI-I-067251/2021|EPI_ISL_1572037|2021-03-27
4
9hCoV-19/Germany/un-RKI-I-062718/2021|EPI_ISL_1568108|2021-03-26
8
hCoV-19/Germany/BY-RKI-I-059506/2021|EPI_ISL_1563971|2021-03-21
18
1hCoV-19/Slovakia/UVZ_PL9_G10_8055/2021|EPI_ISL_1599263|2021-03-29
00
11
hCoV-19/Slovakia/UVZ_PL9_H10_8056/2021|EPI_ISL_1599264|2021-03-29
4hCoV-19/Germany/BY-RKI-I-065260/2021|EPI_ISL_1570373|2021-03-19
4
34
hCoV-19/Germany/BY-RKI-I-066850/2021|EPI_ISL_1571623|2021-03-30
13hCoV-19/Germany/BY-RKI-I-070546/2021|EPI_ISL_1574650|2021-04-02
030
hCoV-19/Germany/BY-RKI-I-070389/2021|EPI_ISL_1574502|2021-04-02
30
hCoV-19/Germany/BY-RKI-I-059920/2021|EPI_ISL_1565471|2021-03-25
97
1hCoV-19/France/IDF-IPP04986/2021|EPI_ISL_1263057|2021-03-02
00
hCoV-19/France/BRE-IPP08194/2021|EPI_ISL_1583042|2021-03-27
hCoV-19/France/CVL-IPP05580/2021|EPI_ISL_1621485|2021-03-10
71
hCoV-19/England/ALDP-130C37E/2021|EPI_ISL_1100238|2021-02-19
9hCoV-19/France/IDF-IPP05174/2021|EPI_ISL_1381817|2021-03-09
9
hCoV-19/France/IDF-HMN-21032110290/2021|EPI_ISL_1404459|2021-03-09
100
hCoV-19/France/HDF-IPP06027/2021|EPI_ISL_1389320|2021-03-15
1hCoV-19/Sweden/SE00380890/2021|EPI_ISL_1607361|2021-03-26
7
1hCoV-19/Sweden/SE00378473/2021|EPI_ISL_1607439|2021-03-25
1hCoV-19/Sweden/SE00369578/2021|EPI_ISL_1607160|2021-03-22
4
hCoV-19/Sweden/SE00375652/2021|EPI_ISL_1607184|2021-03-24
1274
hCoV-19/Sweden/SE00368314/2021|EPI_ISL_1607483|2021-03-22
3hCoV-19/Sweden/SE00384778/2021|EPI_ISL_1607422|2021-03-27
4hCoV-19/Sweden/SUS0000573/2021|EPI_ISL_1534092|2021-03-30
1hCoV-19/Sweden/SE00363731/2021|EPI_ISL_1605457|2021-03-19
00
14
hCoV-19/Sweden/SUS0000669/2021|EPI_ISL_1629509|2021-03-29
41hCoV-19/Sweden/SUS0000650/2021|EPI_ISL_1629490|2021-03-31
45
hCoV-19/Sweden/SUS0000854/2021|EPI_ISL_1629694|2021-04-10
33
25
hCoV-19/Sweden/SUS0000659/2021|EPI_ISL_1629499|2021-03-22
2hCoV-19/Sweden/SUS0000448/2021|EPI_ISL_1468482|2021-03-19
4
5hCoV-19/Sweden/SUS0000526/2021|EPI_ISL_1534045|2021-03-27
3
1 0 0 hCoV-19/Sweden/SUS0000745/2021|EPI_ISL_1629585|2021-03-26
5hCoV-19/Sweden/SE00364496/2021|EPI_ISL_1604766|2021-03-19
4
99
hCoV-19/Sweden/SE00368676/2021|EPI_ISL_1607487|2021-03-22
100
hCoV-19/Sweden/SE00349281/2021|EPI_ISL_1603155|2021-03-13
7hCoV-19/USA/NY-MSHSPSP-PV27616/2021|EPI_ISL_1300810|2021-02-07
8
99
hCoV-19/USA/PA-VSP1380/2021|EPI_ISL_1621352|2021-03-14
hCoV-19/USA/OR-OHSU-PHL00037/2021|EPI_ISL_1055380|2021-02-06
78
67
hCoV-19/USA/PA-CHOP_204/2021|EPI_ISL_1629709|2021-03-24
1 0 0 hCoV-19/Poland/PL_P83/2021|EPI_ISL_1340956|2021-03-09
33
hCoV-19/Poland/PL-P1078/2021|EPI_ISL_1499206|2021-03-15
hCoV-19/USA/FL-CDC-QDX23214975/2021|EPI_ISL_1552460|2021-03-23
98
36
hCoV-19/USA/CT-JAX-JAX000930/2021|EPI_ISL_1625614|2021-04-09
45
hCoV-19/USA/CT-JAX-JAX000245/2021|EPI_ISL_1315160|2021-03-12
hCoV-19/Germany/NW-RKI-I-053867/2021|EPI_ISL_1437372|2021-03-05
hCoV-19/Italy/EMR-099437-009-01/2021|EPI_ISL_1404435|2021-03-18
hCoV-19/Turkey/HSGM-33/2021|EPI_ISL_1534527|2021-03-16
hCoV-19/USA/NY-PRL-2021_03_05_00K17/2021|EPI_ISL_1173118|2021-03-02
30
hCoV-19/USA/NY-PRL-2021_0210_04E07/2021|EPI_ISL_995070|2021-02-08
43
52
hCoV-19/USA/NY-PRL-2021_03_01_00J22/2021|EPI_ISL_1172481|2021-02-26
hCoV-19/USA/NY-PRL-2021_03_22_01D03/2021|EPI_ISL_1385215|2021-03-20
hCoV-19/Italy/CAM-AMES-68-85/2021|EPI_ISL_1558386|2021-03-18
99

17

30

39

47

MN908947.3
2.0E-4

B

213

13

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

214

Supplementary Table 1. Excel Sheet of GNUVID results for the 236 isolates.

215

Supplementary Table 2. Mutations and deletions in CHOP_204 compared to

216

MN908947.3.
Mutation

Protein

AA change

Frequency

C241T

-

-

1

C913T

ORF1ab

synonymous

0.92

C1059T

ORF1ab

T265I

0.33

C2110T

ORF1ab

synonymous

0.98

C3037T

ORF1ab

synonymous

1

C3267T

ORF1ab

T1001I

0.64

C4320T

ORF1ab

synonymous

0.38

C5388A

ORF1ab

A1708D

0.65

C5986T

ORF1ab

synonymous

0.62

T6954C

ORF1ab

I2230T

0.74

T7984C

ORF1ab

synonymous

0.65

T9867C

ORF1ab

L3201P

0.33

11288 (del-9)

ORF1ab

SGF3675-77 deletion

0.99

C12781T

ORF1ab

synonymous

0.96

C14120T

ORF1ab

Q4619*

0.95

C14408T

ORF1ab

synonymous

1

C14676T

ORF1ab

P4804L

0.96

C15279T

ORF1ab

T5005I

0.66

T16176C

ORF1ab

L5304P

0.72

A16500C

ORF1ab

K5412T

0.30

C16887T

ORF1ab

synonymous

0.31

C19390T

ORF1ab

synonymous

1

C21575T

S

L5F

0.35

21765 (del6)

S

HV69-70 deletion

0.99

21991 (del3)

S

Y144 deletion

0.98

G23012A

S

E484K

0.77

A23063T

S

N501Y

0.95

C23271A

S

A570D

1

A23403G

S

D614G

1

14

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

C23604A

S

P681H

0.98

C23664T

S

A701V

0.41

C23709T

S

T716I

0.99

T24506G

S

S982A

0.55

G24914C

S

D1118H

0.94

C25517T

ORF3a

P42L

0.36

C27972T

ORF8

Q27*

0.93

A28095T

ORF8

K68*

0.93

A28111G

ORF8

Y73C

0.96

A28271 (del1)

-

deletion

0.97

GAT28280CTA

N

D3L

0.97

C28869T

N

P199L

0.38

GGG28881AAC

N

R203K, G204R

0.55

C28977T

N

S235F

0.88

C29137T

N

synonymous

0.54

217
218

Supplementary Table 3. GISAID Acknowledgement Table.

219
220
221
222
223
224
225
226
227
228

15

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

229

Supplementary Figure 1. SNP variations in all available 20I/501Y.V1+E484K

230

isolates.

231
232

16

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274

References
1
2

3
4
5
6
7
8
9
10
11
12

13
14
15
16

Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7
in England. Science, eabg3055, doi:10.1126/science.abg3055 (2021).
Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory
syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in
South Africa. medRxiv, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640
(2020).
Faria, N. R. et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus,
Brazil. medRxiv, 2021.2002.2026.21252554, doi:10.1101/2021.02.26.21252554 (2021).
Rambaut, A., et al. Preliminary genomic characterisation of an emergent SARS-CoV-2
lineage in the UK defined by anovel set of spike mutations. https://virological.org/t/563
(2020).
Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and
serum-derived polyclonal antibodies. Nature Medicine, doi:10.1038/s41591-021-01294w (2021).
Volz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from
linking epidemiological and genetic data. medRxiv, 2020.2012.2030.20249034,
doi:10.1101/2020.12.30.20249034 (2021).
Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein
variants. eLife 9, e61312, doi:10.7554/eLife.61312 (2020).
Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
vaccine-induced sera. Cell, doi:10.1016/j.cell.2021.02.037.
Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by
vaccine-induced humoral immunity. Cell, doi:10.1016/j.cell.2021.03.013 (2021).
Wu, K. et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med,
doi:10.1056/NEJMc2102179 (2021).
Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Nature, doi:10.1038/s41586-021-03412-7 (2021).
Public Health England. Investigation of novel SARS-CoV-2 variant: Variant of Concern
202012/01 (Technical briefing 5).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme
nt_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf
(2021).
Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision
to reality. Euro Surveill 22, doi:10.2807/1560-7917.ES.2017.22.13.30494 (2017).
Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
genomic epidemiology. Nat Microbiol, doi:10.1038/s41564-020-0770-5 (2020).
Moustafa, A. M. & Planet, P. J. Emerging SARS-CoV-2 diversity revealed by rapid whole
genome sequence typing. bioRxiv, doi:10.1101/2020.12.28.424582 (2020).
Wu, F. et al. A new coronavirus associated with human respiratory disease in China.
Nature 579, 265-269, doi:10.1038/s41586-020-2008-3 (2020).

17

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440801; this version posted April 21, 2021. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294

17
18
19
20
21
22
23

Li, C. et al. Highly sensitive and full-genome interrogation of SARS-CoV-2 using
multiplexed PCR enrichment followed by next-generation sequencing. bioRxiv,
2020.2003.2012.988246, doi:10.1101/2020.03.12.988246 (2020).
Pandey, U. et al. High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation
in Pediatric Patients with COVID-19. Open Forum Infectious Diseases (2020 (In Press)).
Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately
measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol 20, 8,
doi:10.1186/s13059-018-1618-7 (2019).
Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple
sequence alignment based on fast Fourier transform. Nucleic Acids Res 30, 3059-3066,
doi:10.1093/nar/gkf436 (2002).
Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
Inference in the Genomic Era. Mol Biol Evol 37, 1530-1534,
doi:10.1093/molbev/msaa015 (2020).
TavarÈ, S. Some probabilistic and statistical problems in the analysis of DNA sequences.
Lectures on Mathematics in the Life Sciences 17, 57-86 (1986).
Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2:
Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol 35, 518-522,
doi:10.1093/molbev/msx281 (2018).

18

